|Forum - Stocks For A Different Jungle
||If it belongs at the Pit it doesn't belong here.|
|From: blacksheep (Rep: 295)||Date: 02/07/2017 07:30|
|Forum: Stocks For A Different Jungle - Msg #19098||Thread #673904724 (Rec: 0) |
|17.30 Celgene Switzerland Llc Buys 625,000 Shares @16|
Jounce Therapeutics Inc (NASDAQ:JNCE) major shareholder Celgene Switzerland Llc bought 625,000 shares of Jounce Therapeutics stock in a transaction that occurred on Wednesday, February 1st. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Jounce Therapeutics Inc (NASDAQ:JNCE) opened at 17.05 on Monday. The company’s market capitalization is $136.74 million. The stock’s 50 day moving average price is $17.00 and its 200-day moving average price is $17.00. Jounce Therapeutics Inc has a 52 week low of $16.33 and a 52 week high of $18.50.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.